CN102164952B - 新型组合物和方法 - Google Patents

新型组合物和方法 Download PDF

Info

Publication number
CN102164952B
CN102164952B CN200980138400.6A CN200980138400A CN102164952B CN 102164952 B CN102164952 B CN 102164952B CN 200980138400 A CN200980138400 A CN 200980138400A CN 102164952 B CN102164952 B CN 102164952B
Authority
CN
China
Prior art keywords
seq
polypeptide
sequence
cell
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980138400.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN102164952A (zh
Inventor
J·布朗
P·梅滕斯
D·墨菲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Glaxo Group Ltd
Original Assignee
GlaxoSmithKline Biologicals SA
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA, Glaxo Group Ltd filed Critical GlaxoSmithKline Biologicals SA
Publication of CN102164952A publication Critical patent/CN102164952A/zh
Application granted granted Critical
Publication of CN102164952B publication Critical patent/CN102164952B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
CN200980138400.6A 2008-07-25 2009-07-24 新型组合物和方法 Expired - Fee Related CN102164952B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8372008P 2008-07-25 2008-07-25
US61/083720 2008-07-25
PCT/EP2009/059580 WO2010010177A1 (en) 2008-07-25 2009-07-24 Novel compositions and methods

Publications (2)

Publication Number Publication Date
CN102164952A CN102164952A (zh) 2011-08-24
CN102164952B true CN102164952B (zh) 2016-05-25

Family

ID=41217660

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980138400.6A Expired - Fee Related CN102164952B (zh) 2008-07-25 2009-07-24 新型组合物和方法

Country Status (24)

Country Link
US (2) US20110117119A1 (enExample)
EP (1) EP2315773B1 (enExample)
JP (1) JP5873332B2 (enExample)
KR (1) KR20110044883A (enExample)
CN (1) CN102164952B (enExample)
AU (1) AU2009273130B2 (enExample)
BR (1) BRPI0916703A2 (enExample)
CA (1) CA2731499C (enExample)
CO (1) CO6341637A2 (enExample)
CY (1) CY1118200T1 (enExample)
DK (1) DK2315773T3 (enExample)
EA (1) EA024826B1 (enExample)
ES (1) ES2602430T3 (enExample)
HR (1) HRP20161458T1 (enExample)
HU (1) HUE031044T2 (enExample)
IL (1) IL210559A0 (enExample)
LT (1) LT2315773T (enExample)
MX (1) MX2011000983A (enExample)
PL (1) PL2315773T3 (enExample)
PT (1) PT2315773T (enExample)
SG (1) SG192456A1 (enExample)
SI (1) SI2315773T1 (enExample)
UA (1) UA107330C2 (enExample)
WO (1) WO2010010177A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69941545D1 (de) * 1998-11-04 2009-11-26 Isis Innovation Tuberkulose diagnose test
HRP20181353T1 (hr) 2008-07-25 2018-10-19 Glaxosmithkline Biologicals S.A. Tuberkulozni protein rv2386c, njegovi pripravci i upotreba
NO2315597T3 (enExample) 2008-07-25 2018-01-20
EP2156945A1 (en) 2008-08-13 2010-02-24 Novelis Inc. Clad automotive sheet product
EP2421557B1 (en) 2009-04-24 2018-12-05 Statens Serum Institut A tuberculosis tb vaccine to prevent reactivation
LT2528621T (lt) 2010-01-27 2016-12-12 Glaxosmithkline Biologicals S.A. Modifikuoti tuberkuliozės antigenai
DK3049973T3 (en) 2013-09-27 2018-10-22 Codexis Inc AUTOMATED SCREENING OF ENZYM VARIENTS
WO2015048573A1 (en) 2013-09-27 2015-04-02 Codexis, Inc. Structure based predictive modeling
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
CN106546737A (zh) * 2016-10-24 2017-03-29 广州迪澳医疗科技有限公司 一种体外检测活动性结核的方法
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
GB2600652B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel compositions
JP2021504424A (ja) 2017-12-01 2021-02-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
KR102947433B1 (ko) 2019-04-12 2026-04-06 씨4 테라퓨틱스, 인코포레이티드 이카로스 및 아이올로스의 트리시클릭 분해제
WO2020245207A1 (en) 2019-06-05 2020-12-10 Glaxosmithkline Biologicals Sa Saponin purification
KR20240049802A (ko) * 2021-08-31 2024-04-17 비르 바이오테크놀로지, 인코포레이티드 결핵 백신
CN115073612B (zh) * 2022-06-22 2024-09-27 宁夏大学 一种结核分枝杆菌Zera-71cA蛋白纳米颗粒、制备方法及其用途
GB202318595D0 (en) * 2023-12-05 2024-01-17 Sec Dep For Environment Food And Rural Affairs Acting Through Animal And Plant Health Agency Diagnostic proteins and reagents

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2290774A1 (en) * 1997-05-20 1998-11-26 Corixa Corporation Mycobacterium tuberculosis antigens for immunotherapy and diagnosis of tuberculosis
CA2326598A1 (en) * 1998-04-07 1999-10-14 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
WO2001062893A2 (en) * 2000-02-25 2001-08-30 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2133100E (pt) * 2000-06-20 2012-01-11 Corixa Corp Antigénio mtb32a de mycobacterium tuberculosis com um local activo inactivado e suas proteínas de fusão
AU2002219338B2 (en) * 2001-01-08 2006-12-14 Oxford Immunotec Limited Assay to determine efficacy of treatment for mycobacterial infection
US20040121322A9 (en) * 2001-02-22 2004-06-24 Cole Stewart T. Comparative mycobacterial genomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses
US20030236393A1 (en) * 2002-03-22 2003-12-25 United States Of America Dept Of Vetrans Affairs Virulence genes of M. marinum and M. tuberculosis
EP2226332A1 (en) * 2004-06-17 2010-09-08 Beckman Coulter, Inc. Mycobacterium tuberculosis epitopes and methods of use thereof
PT2426141E (pt) 2005-04-29 2014-11-25 Glaxosmithkline Biolog Sa Método para prevenção ou tratamento de uma infecção por m. tuberculosis
US7968105B2 (en) * 2005-06-23 2011-06-28 Statens Serum Institut Tuberculosis vaccines comprising antigens expressed during the latent infection phase
WO2008007942A1 (en) * 2006-07-10 2008-01-17 Het Nederlands Kanker Instituut Means and methods for manipulating sequential phagolysomal-cytosolic translocation of mycobacteria, and uses thereof
EP2087128A4 (en) * 2006-11-01 2009-11-04 Immport Therapeutics Inc COMPOSITIONS AND METHODS FOR IMMUNOMINANT ANTIGENES
EP2421557B1 (en) * 2009-04-24 2018-12-05 Statens Serum Institut A tuberculosis tb vaccine to prevent reactivation
LT2528621T (lt) 2010-01-27 2016-12-12 Glaxosmithkline Biologicals S.A. Modifikuoti tuberkuliozės antigenai

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2290774A1 (en) * 1997-05-20 1998-11-26 Corixa Corporation Mycobacterium tuberculosis antigens for immunotherapy and diagnosis of tuberculosis
US6613881B1 (en) * 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
CA2326598A1 (en) * 1998-04-07 1999-10-14 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
WO2001062893A2 (en) * 2000-02-25 2001-08-30 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis

Also Published As

Publication number Publication date
UA107330C2 (uk) 2014-12-25
US9795663B2 (en) 2017-10-24
US20140178423A1 (en) 2014-06-26
EP2315773B1 (en) 2016-08-24
ES2602430T3 (es) 2017-02-21
PL2315773T3 (pl) 2017-07-31
CY1118200T1 (el) 2017-06-28
HRP20161458T1 (hr) 2016-12-16
HUE031044T2 (en) 2017-06-28
LT2315773T (lt) 2016-11-10
AU2009273130B2 (en) 2014-10-16
US20110117119A1 (en) 2011-05-19
SG192456A1 (en) 2013-08-30
CA2731499C (en) 2017-01-10
CO6341637A2 (es) 2011-11-21
BRPI0916703A2 (pt) 2019-12-24
MX2011000983A (es) 2011-03-02
JP2011528895A (ja) 2011-12-01
DK2315773T3 (en) 2016-12-12
PT2315773T (pt) 2016-11-23
KR20110044883A (ko) 2011-05-02
CN102164952A (zh) 2011-08-24
AU2009273130A1 (en) 2010-01-28
CA2731499A1 (en) 2010-01-28
WO2010010177A1 (en) 2010-01-28
JP5873332B2 (ja) 2016-03-01
EP2315773A1 (en) 2011-05-04
EA201100072A1 (ru) 2011-10-31
EA024826B1 (ru) 2016-10-31
SI2315773T1 (sl) 2016-12-30
IL210559A0 (en) 2011-03-31

Similar Documents

Publication Publication Date Title
CN102165064B (zh) 结核病rv2386c蛋白、组合物及其用途
JP5873332B2 (ja) 新規化合物および方法
CN102164612B (zh) 新型组合物和方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160525